← Back to Cancer ScreeningNot FDA approved
Delfi Diagnostics
High-risk lung cancer patients (smokers)
Variable
Test Performance
Sensitivity
80% sensitivity
Specificity
58% specificity
Detection Method
Fragmentomics
Turnaround
10-14 days
Key Features
Lung cancer screening • Fragmentomics technology • Complements LDCT • High-risk patients
Who It's For
Important Notes
Novel fragmentomics approach - applies machine learning to whole-genome sequencing of cfDNA fragmentation patterns. Complements rather than replaces low-dose CT screening. 99.8% negative predictive value;an elevated result raises the likelihood of finding lung cancer on LDCT by 5.2x. For adults 50-80 with a 20 pack-year smoking history. CLIA LDT, not FDA approved. Now authorised in all 50 states following its New York State permit in 2026.
Learn more about Delfi Diagnostics
Discuss with your physician before ordering.
Visit Delfi DiagnosticsCompare All